A Phase I Dose-Escalation Study of the Selective PKC- Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of MS-553 in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Sponsor: MindSight Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR9532
U.S. Govt. ID: NCT03492125
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: MS-553 is being tested for its potential to block a specific enzyme (Protein Kinase C) that is known to play a role in the growth and survival of cancer cells in different types of leukemia. The purpose of this study is to determine the safety, recommended dose and preliminary activity of MS-553 in treating CLL/SLL.
Nicole Lamanna, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have CLL or SLL? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator